1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209–49. doi: 10.3322/caac.21660.
2. van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–84. doi: 10.1056/NEJMoa1112088.
3. Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. The Lancet 2017;390:2383–96. doi: 10.1016/S0140-6736(17)31462-9.
4. Shang Q-X, Yang Y-S, Hu W-P, Yuan Y, Ji A-F, Chen L-Q. Prognostic significance and role of thoracic lymph node metastasis based on Chinese expert consensus in esophageal cancer. Ann Transl Med 2019;7:381. doi: 10.21037/atm.2019.07.63.
5. 杨欢, 孙宛怡, 王建炳, 王晓坤, 张锦雨, 范金虎, et al. 中国食管癌病因学、筛查及早期诊断研究进展. 肿瘤防治研究
YANG H , SUN WY , WANG JB,et al.Research Progress of Etiology, Screening and Early Diagnosis of Esophageal Cancer in China, Cancer Research on Prevention and Teatment. 2022;49 (3):169–75.
6. Jiang Z, Wang J, Shen Z, Zhang Z, Wang S. Characterization of Esophageal Microbiota in Patients With Esophagitis and Esophageal Squamous Cell Carcinoma. Front Cell Infect Microbiol 2021;11:774330. doi: 10.3389/fcimb.2021.774330.
7. Fernández-Montes A, Alcaide J, Alsina M, Custodio AB, Franco LF, Gallego Plazas J, et al. SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021). Clin Transl Oncol 2022;24:658–69. doi: 10.1007/s12094-022-02801-2.
8. Wu S-G, Zhang W-W, Sun J-Y, Li F-Y, Lin Q, He Z-Y. Patterns of Distant Metastasis Between Histological Types in Esophageal Cancer. Front Oncol 2018;8:302. doi: 10.3389/fonc.2018.00302.
9. Wang Z, Mao Y, Gao S, Li Y, Tan L, Daiko H, et al. Lymph node dissection and recurrent laryngeal nerve protection in minimally invasive esophagectomy. Ann N Y Acad Sci 2020;1481:20–9. doi: 10.1111/nyas.14427.
10. Copur MS, Manapuram S. Multiple Primary Tumors Over a Lifetime. Oncology (Williston Park) 2019;33:629384.
11. Baba Y, Yoshida N, Kinoshita K, Iwatsuki M, Yamashita Y-I, Chikamoto A, et al. Clinical and Prognostic Features of Patients With Esophageal Cancer and Multiple Primary Cancers: A Retrospective Single-institution Study. Ann Surg 2018;267:478–83. doi: 10.1097/SLA.0000000000002118.
12. Liu J, Liu Q, Wang Y, Xia Z, Zhao G. Nodal skip metastasis is associated with a relatively poor prognosis in thoracic esophageal squamous cell carcinoma. Eur J Surg Oncol 2016;42:1202–5. doi: 10.1016/j.ejso.2016.05.025.
13. Müller M, Posch F, Kiem D, Barth D, Horvath L, Stotz M, et al. Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis. Ther Adv Med Oncol 2021;13:17588359211039930. doi: 10.1177/17588359211039930.
14. Shim H-J, Cho S-H, Hwang J-E, Bae W-K, Song S-Y, Cho S-B, et al. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer. Am J Clin Oncol 2010;33:624–8. doi: 10.1097/COC.0b013e3181bead92.
15. Thallinger CMR, Raderer M, Hejna M. Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol 2011;29:4709–14. doi: 10.1200/JCO.2011.36.7599.
16. Yoshioka T, Sakayori M, Kato S, Chiba N, Miyazaki S, Nemoto K, et al. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. Int J Clin Oncol 2006;11:454–60. doi: 10.1007/s10147-006-0610-5.
17. Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ 2022;377:e068714. doi: 10.1136/bmj-2021-068714.
18. Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, et al. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). Nat Commun 2022;13:857. doi: 10.1038/s41467-022-28408-3.
19. Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, et al. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol 2018;36:2836–44. doi: 10.1200/JCO.2017.76.6212.
20. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial - PubMed. (May 17, 2022). Retrieved from https://pubmed.ncbi.nlm.nih.gov/34519801/.
21. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398:27–40. doi: 10.1016/S0140-6736(21)00797-2.
22. Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 2022;386:449–62. doi: 10.1056/NEJMoa2111380.
23. Smyth EC, Lordick F. Nivolumab for previously treated squamous oesophageal carcinoma. Lancet Oncol 2019;20:1468–9. doi: 10.1016/S1470-2045(19)30621-7.
24. Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3) - PubMed. (May 12, 2022). Retrieved from https://pubmed.ncbi.nlm.nih.gov/33170461/.
25. Kato K, Cho BC, Takahashi M, Okada M, Lin C-Y, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:1506–17. doi: 10.1016/S1470-2045(19)30626-6.
26. Sun J-M, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021;398:759–71. doi: 10.1016/S0140-6736(21)01234-4.
27. Wang Z-X, Cui C, Yao J, Zhang Y, Li M, Feng J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell 2022;40:277-288.e3. doi: 10.1016/j.ccell.2022.02.007.
28. Huang J, Xu B, Liu Y, Huang J, Lu P, Ba Y, et al. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial. Cancer Commun (Lond) 2019;39:16. doi: 10.1186/s40880-019-0359-7.
29. Li L-Q, Fu Q-G, Zhao W-D, Wang Y-D, Meng W-W, Su T-S. Chemoradiotherapy Versus Chemotherapy Alone for Advanced Esophageal Squamous Cell Carcinoma: The Role of Definitive Radiotherapy for Primary Tumor in the Metastatic Setting. Front Oncol 2022;12:824206. doi: 10.3389/fonc.2022.824206.
30. Li C, Wang X, Wang L, Chen J, Zhang W, Pang Q, et al. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. Acta Oncol 2021;60:627–34. doi: 10.1080/0284186X.2021.1902564.
31. Guttmann DM, Mitra N, Bekelman J, Metz JM, Plastaras J, Feng W, et al. Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer. J Thorac Oncol 2017;12:1131–42. doi: 10.1016/j.jtho.2017.03.026.
32. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167–74. doi: 10.1200/JCO.2002.20.5.1167.
33. Willett CG. Radiation dose escalation in combined-modality therapy for esophageal cancer. J Clin Oncol 2002;20:1151–3. doi: 10.1200/JCO.2002.20.5.1151.
34. Sakanaka K, Ishida Y, Fujii K, Ishihara Y, Nakamura M, Hiraoka M, et al. Radiation Dose-escalated Chemoradiotherapy Using Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Unresectable Thoracic Oesophageal Squamous Cell Carcinoma: A Single-institution Phase I Study. Clin Oncol (R Coll Radiol) 2021;33:191–201. doi: 10.1016/j.clon.2020.07.012.
35. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16:187–99. doi: 10.1016/S1470-2045(14)71207-0.
36. Ren XJ, Wang L, Han C, Liu LL. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma]. Zhonghua Zhong Liu Za Zhi 2019;41:135–9. doi: 10.3760/cma.j.issn.0253-3766.2019.02.011.
37. Gao L-R, Wang X, Han W, Deng W, Li C, Wang X, et al. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. BMC Cancer 2020;20:901. doi: 10.1186/s12885-020-07387-y.
38. Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu C-H, et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol 2020;38:4138–48. doi: 10.1200/JCO.20.01888.
39. Hong Y, Wu T, Lu P, Chang Z, Liang W, Zhang G, et al. Real-world effectiveness of anlotinib in combination with PD-1 inhibitors as second-line or later therapy for advanced or metastatic esophageal squamous cell carcinoma. JCO 2022;40:320–320. doi: 10.1200/JCO.2022.40.4_suppl.320.
40. Yang H, Wang K, Li Y, Li S, Yuan L, Ge H. Local Ablative Treatment Improves Survival in ESCC Patients With Specific Metastases, 2010-2016: A Population-Based SEER Analysis. Front Oncol 2022;12:783752. doi: 10.3389/fonc.2022.783752.